American Conference Institute is holding its ninth annual “Maximizing Pharmaceutical Patent Life Cycles” conference October 15-16 in New York. According to ACI, this “definitive Hatch-Waxman event provides the crucial information for pharmaceutical patent counsel to cultivate, modify, and enhance a foundation for their life cycle strategies.”
The agenda includes many topics covered on Orange Book Blog. Selected talks include:
- “Constructing, Adjusting, and Executing a Pharmaceutical Patent Life Cycle Management Plan”
- “View from the FTC,” presented by Saralisa Brau, Health Care Services and Products Division, FTC
- “Navigating the Complexity of Structuring Patent Settlement Options Between Brand Name and Generic Pharmaceutical Companies”
- “Eye on the Bench: Identifying Judicial Trends in Pharmaceutical Patent Cases”
- “Mastering the Intricacies of the 180-Day Generic Market Exclusivity”
- “Plotting a Course Into Safe Harbor for Branded Pharma”
- “View from the FDA,” presented by Elizabeth Dickinson, Office of Chief Counsel, FDA
- “Slicing Through the Complex Spectrum of Declaratory Judgment Actions in Pharmaceutical Patent Cases”
- “Factoring the Role, Challenges, and Impact of Orange Book Listings and Delistings in Patent Portfolio Management”
In addition, two optional post-conference workshops are offered on October 17th: a brand name master class entitled “Overpowering the Challenges in Increasing the Pharmaceutical Patent Life Cycle Through Patent Extensions” and a generics master class entitled “Adding Value to Paragraph IV Certifications and Notice Letters.”
For more information or to register, please visit the conference website.
Orange Book Blog readers can save $200 by using registration code S.

Leave a comment